Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study

Diabetes Care

Volumn 33, Issue 7, 2010, Pages 1509-1515

  Arnolds, Sabine ^a   Dellweg, Sibylle ^a   Clair, Janina ^a   Dain, Marie Paule ^b   Nauck, Michael A ^c   Rave, Klaus ^a   Kapitza, Christoph ^a  

^a Profil Institut fur Stoffwechselforschung   (Germany)

^b SANOFI   (France)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIPHASIC INSULIN; EXENDIN 4; GLUCOSE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; NHP INSULIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; PEPTIDE; VENOM;

ADD ON THERAPY; ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARM; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; MEAL; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; DRUG COMBINATION; HYPERGLYCEMIA; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 77955262909     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2191     Document Type: Article

References (25)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972 (Pubitemid 44156663)
3. van Avendonk MJ, Rutten GE. Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes Metab 2009;11:415-432
4. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999;42:406-412
5. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-2073 (Pubitemid 38989258)
6. Owens DR, Bolli GB. Beyond the era of NPH insulin - long-acting insulin analogs: chemistry comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333-349
7. sanofi-aventis Deutschland. Lantus. Summary of product characteristics [article online], 2008. Available from http://www.fachinfo.de. Accessed 10 June 2009
8. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003;26:3080-3086
9. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-932
10. Lilly Deutschland. Byetta. Summary of product characteristics, [article online], 2009. Available from http://www.fachinfo.de. Accessed 10 June 2009
11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091
12. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-569
13. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
15. MSD Sharp & Dohme. Januvia. Summary of product characteristics, [article online], 2008. Available from http://www.fachinfo.de. Accessed 10 June 2009
16. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus. What is their place in therapy? Drugs 2008;68:2131-2162
17. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol 2009;70:343-353
18. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122:S3-S10
19. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009;122:S11-S24
20. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med 2009;122:S25-S36
21. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009;122:S37-S50
22. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA general assembly, Washington 2002, and the Note of Clarification on Paragraph 30 by the WMA general assembly, Tokyo 2004
23. Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med 2006;23:240-245
24. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-254
25. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269